TY - JOUR
T1 - AngiomiRs
T2 - MicroRNAs driving angiogenesis in cancer (Review)
AU - Salinas-Vera, Yarely M.
AU - Marchat, Laurence A.
AU - Gallardo-Rincón, Dolores
AU - Ruiz-García, Erika
AU - Astudillo-De la Vega, Horacio
AU - Echavarría-Zepeda, Raquel
AU - López-Camarillo, César
N1 - Publisher Copyright:
© 2019 Spandidos Publications. All rights reserved.
PY - 2019/2
Y1 - 2019/2
N2 - Angiogenesis is an important hallmark of cancer serving a key role in tumor growth and metastasis. Therefore, tumor angiogenesis has become an attractive target for development of novel drug therapies. An increased amount of anti-angiogenic compounds is currently in preclinical and clinical development for personalized therapies. However, resistance to current angiogenesis inhibitors is emerging, indicating that there is a need to identify novel anti-angiogenic agents. In the last decade, the field of microRNA biology has exploded revealing unsuspected functions in tumor angiogenesis. These small non-coding RNAs, which have been dubbed as angiomiRs, may target regulatory molecules driving angiogenesis, such as cytokines, metalloproteinases and growth factors, including vascular endothelial growth factor, platelet-derived growth factor, fibroblast growth factor, epidermal growth factor, hypoxia inducible factor-1, as well as mitogen-activated protein kinase, phosphoinositide 3-kinase and transforming growth factor signaling pathways. The present review discusses the current progress towards understanding the functions of miRNAs in tumor angiogenesis regulation in diverse types of human cancer. Furthermore, the potential clinical application of angiomiRs towards anti-angiogenic tumor therapy was explored.
AB - Angiogenesis is an important hallmark of cancer serving a key role in tumor growth and metastasis. Therefore, tumor angiogenesis has become an attractive target for development of novel drug therapies. An increased amount of anti-angiogenic compounds is currently in preclinical and clinical development for personalized therapies. However, resistance to current angiogenesis inhibitors is emerging, indicating that there is a need to identify novel anti-angiogenic agents. In the last decade, the field of microRNA biology has exploded revealing unsuspected functions in tumor angiogenesis. These small non-coding RNAs, which have been dubbed as angiomiRs, may target regulatory molecules driving angiogenesis, such as cytokines, metalloproteinases and growth factors, including vascular endothelial growth factor, platelet-derived growth factor, fibroblast growth factor, epidermal growth factor, hypoxia inducible factor-1, as well as mitogen-activated protein kinase, phosphoinositide 3-kinase and transforming growth factor signaling pathways. The present review discusses the current progress towards understanding the functions of miRNAs in tumor angiogenesis regulation in diverse types of human cancer. Furthermore, the potential clinical application of angiomiRs towards anti-angiogenic tumor therapy was explored.
KW - Angiogenesis
KW - Cancer
KW - MicroRNAs
KW - Therapy
KW - Tumor neovascularization
UR - http://www.scopus.com/inward/record.url?scp=85060058753&partnerID=8YFLogxK
U2 - 10.3892/ijmm.2018.4003
DO - 10.3892/ijmm.2018.4003
M3 - Artículo
C2 - 30483765
SN - 1107-3756
VL - 43
SP - 657
EP - 670
JO - International Journal of Molecular Medicine
JF - International Journal of Molecular Medicine
IS - 2
ER -